Thermo Fisher Scientific (TMO) Free Cash Flow (2009 - 2026)

Thermo Fisher Scientific has disclosed Free Cash Flow across 18 years of filings, most recently posting $816.0 million for Q1 2026.

• Quarterly Free Cash Flow rose 126.04% year-over-year to $816.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 billion (changed 0.36% YoY) and the FY2025 annual result came in at $6.3 billion, down 13.4% from the prior year.
• Free Cash Flow eased to $816.0 million in Q1 2026, from $3.0 billion in the prior quarter.
• Over five years, Free Cash Flow peaked at $3.3 billion in Q4 2023 and troughed at $271.0 million in Q2 2023.
• A 5-year average of $1.7 billion and a median of $1.6 billion in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2023 — Free Cash Flow slumped 82.65% — and 2024, when it soared 233.58%.
• Tracing TMO's Free Cash Flow over 5 years: stood at $2.9 billion in 2022, then increased by 12.97% to $3.3 billion in 2023, then dropped by 15.31% to $2.8 billion in 2024, then gained by 6.48% to $3.0 billion in 2025, then plunged by 72.73% to $816.0 million in 2026.
• Business Quant data shows TMO's Free Cash Flow at $816.0 million in Q1 2026, $3.0 billion in Q4 2025, and $1.8 billion in Q3 2025.